ES406590A1 - Procedimiento para la vacunacion preventiva contra viruela. - Google Patents

Procedimiento para la vacunacion preventiva contra viruela.

Info

Publication number
ES406590A1
ES406590A1 ES406590A ES406590A ES406590A1 ES 406590 A1 ES406590 A1 ES 406590A1 ES 406590 A ES406590 A ES 406590A ES 406590 A ES406590 A ES 406590A ES 406590 A1 ES406590 A1 ES 406590A1
Authority
ES
Spain
Prior art keywords
contg
vaccinia virus
attenuated vaccinia
smallpox vaccine
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES406590A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BAYERN FREISTAAT
Original Assignee
BAYERN FREISTAAT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19712145477 external-priority patent/DE2145477C3/de
Application filed by BAYERN FREISTAAT filed Critical BAYERN FREISTAAT
Publication of ES406590A1 publication Critical patent/ES406590A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES406590A 1971-09-11 1972-09-11 Procedimiento para la vacunacion preventiva contra viruela. Expired ES406590A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19712145477 DE2145477C3 (de) 1971-09-11 Impfstoff für die intracutane Pockenschutzimpfung

Publications (1)

Publication Number Publication Date
ES406590A1 true ES406590A1 (es) 1975-09-16

Family

ID=5819271

Family Applications (1)

Application Number Title Priority Date Filing Date
ES406590A Expired ES406590A1 (es) 1971-09-11 1972-09-11 Procedimiento para la vacunacion preventiva contra viruela.

Country Status (5)

Country Link
AT (1) AT320149B (enExample)
BE (1) BE787901A (enExample)
CH (1) CH568392A5 (enExample)
DK (1) DK137392C (enExample)
ES (1) ES406590A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
JPS60202827A (ja) * 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP2264178A1 (en) 2002-08-07 2010-12-22 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of Avipoxviruses
EP2371380A1 (en) 2003-03-28 2011-10-05 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
WO2008138533A1 (en) 2007-05-14 2008-11-20 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
AU2010305030A1 (en) 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4358999A1 (en) 2021-06-23 2024-05-01 Consejo Superior De Investigaciones Científicas Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein

Also Published As

Publication number Publication date
BE787901A (fr) 1972-12-18
CH568392A5 (enExample) 1975-10-31
AT320149B (de) 1975-01-27
DK137392C (da) 1978-09-18
DE2145477B2 (de) 1976-04-01
DK137392B (da) 1978-02-27
DE2145477A1 (de) 1973-03-15

Similar Documents

Publication Publication Date Title
ES406590A1 (es) Procedimiento para la vacunacion preventiva contra viruela.
CA924330A (en) High purity hot pressed boron nitride
ES432696A1 (es) Procedimiento de preparacion de vacunas.
ES426215A1 (es) Procedimiento para preparar una vacuna de adenovirus bovi- nos vivos.
CA957168A (en) Steam system
CA945862A (en) Thermodynamic steam trap
CA970110A (en) Low-froth, water-soluble dyeing auxiliaries
CA956130A (en) Steam pressure cooker
ZA715992B (en) Low-froth,water-soluble dyeing auxiliaries
NO137598C (no) Fremgangsmaate til fremstilling av ren, krystallinsk penicillinacylase
SE417097B (sv) 2,4 diamino-5 bensylpyrimidiner till anvendning som mellanprodukter for framstellning av 2,4 diamino-5 bensylpyrimidiner och sett att framstella dem
AU451635B2 (en) Vaccine preparation
SU77221A1 (ru) Терморегул тор, преимущественно дл муфельной печи
CA952169A (en) Skin heating of steel by a.c.
CA943458A (en) Process for producing anhydrous smallpox vaccine
AU4984672A (en) Vaccine adjuvants
CA982123A (en) 1,5-and 1,8-dihydroxy=anthraquinones
DK134518B (da) Analogifremgangsmåde til fremstilling af 4beta-alkoxy-4alfa-(3'-hydroxyphenyl)-3alfa,5alfa-propanopiperidin-derivater.
CA876717A (en) 2,4 disubstituted tetrahydro 1,4-oxazines
CA957892A (en) Cultivator
CA875366A (en) Steam cooled gas turbine
AU3627471A (en) Steam chamber
CA638733A (en) Pressure steam cookers
MATSUURA et al. Utilization of Carbonized Rice Hull as a Medium for Growing Small Rice Seedling for Transplanter
CA875583A (en) Preparation for optically active 3,4-dihydroxyphenyl-alanine